Substituent and solvent effects in the 1,3-dipolar cycloadditions for synthesis of anti-influenza agent peramivir and its analog

Influenza remains a health problem to humans. Peramivir is a FDA approved anti-influenza drug targeting the virus neuraminidase. The (3 + 2) cycloaddition reaction of 2-ethylbutanenitrile oxide with the cyclopentene dipolarophile derived from Vince lactam is a key step in the conventional synthesis of peramivir. Our study showed that conducting the (3 + 2) cycloaddition reactions with either aliphatic or aromatic nitrile oxide in hexane solution provided high percentage of the desired regioisomer, and the N-substituent having electron-withdrawing property is also beneficial to the regioselectivity. This study also demonstrated an alternative synthetic pathway of (−)-peramivir and the analog having a phenyl group in place of the 3-pentyl moiety.     

Structure-based Design,Synthesis and Anti-influenza A Virus Activities of Substituted Phenyl-coupled Heterocyclic Ethylamide Derivatives

A series of new substituted phenyl-coupled heterocyclic ethylamide derivatives was designed and synthesized as anti-influenza agents. In vitro anti-influenza A(A/PR/8/34 H1N1 strain) activities of these compounds were investigated and compared to those of the commercial antiviral drugs(Arbidol and Ribavirin) against the influenza. Specifically, among these twelve compounds exhibiting moderate levels of antiviral activity against influenza A, compounds 30c and 30d are the most effective ones, and as efficacious as the positive control Ribavirin and much more effective than Ingavirin and Arbidol, indicating that they are prospective candidates for further exploration. These results are also consistent with the docking study results in terms of the design of compounds targeting influenza A via viral nucleoprotein.     

神经氨酸酶与三羟基甲氧基黄酮衍生物相互作用的分子模拟

以5,7,4'-三羟基-8-甲氧基黄酮(MF)为先导物, 以现有的神经氨酸酶(NA)抑制剂类药物的结构特征为参考, 设计了一系列的三羟基甲氧基黄酮衍生物, 并运用分子对接与分子动力学相结合的方法进行了筛选及作用机制分析. 分子对接结果表明, 功能团(羧基及胍基/氮-乙酰氨基)的引入并未影响衍生物在酶活性腔中的结合位置, 衍生物的结构与相互作用能之间存在一定的联系. 将羧基和胍基作为替代基团引入到MF的C7及C5位上所得的新化合物(9)在所合成的衍生物中具有最好的结合能力(-1172.52 kJ/mol), 远远优于现有先导药物4-(氮-乙酰氨基)-5-胍基-3-(3-戊氧基)安息香酸(BA)和MF与NA的结合能力(-672.12和-347.44 kJ/mol). 进一步的作用机制分析发现, 在神经氨酸酶活性腔中, 化合物9的羧基和胍基的空间取向与现有药物中这两个基团的空间取向一致, 且化合物9与先导药物MF一样, 能与活性腔内保守残基Asp151和Glu227发生较强的相互作用. 因此可认为化合物9是一种具有应用潜质的新型神经氨酸酶抑制剂. 本研究结果为实验研究和设计抗流感药物提供了可行性思路.     

Molecular Biological Background of the Species and Organ Specificity of Influenza A Viruses

Influenza is one of the great plagues which is not yet under control. The reason for this is the immense variability of the infecting agent, the influenza A viruses. These viruses behave like a chameleon: they adapt very rapidly to varying environments. New strains are “synthesized,” which can escape the immune response of the host, cross species barriers, and become highly pathogenic. We are beginning to understand the molecular background of this extraordinarily high variability. The genome of influenza A viruses consists of eight single-stranded RNA segments, each of which constitutes a gene. The total base sequence of the eight RNA segments of several strains is known. If a suitable organism becomes doubly infected with two different influenza A strains, each of the RNA segments behaves like a chromosome. This means that by reassortment of the 16 RNA segments, 2⁸ ?2 = 254 new combinations (= reassortants) are theoretically possible, each having different properties. Furthermore, mutations in the various RNA segments are relatively easily tolerated. Another great problem resides in the enormous reservoir of different influenza A viruses in the animal kingdom, especially in feral waterbirds. In these birds the avian influenza A viruses normally cause at most mild symptoms, and therefore these viruses are distributed over and between continents. Bearing this in mind it appears to be necessary to develop new ideas as to how to overcome this great plague.     

Pharmacophore modelling,virtual screening and molecular docking studies on PLD1 inhibitors

Lipid metabolism plays a significant role in influenza virus replication and subsequent infection. The regulatory mechanism governing lipid metabolism and viral replication is not properly understood to date, but both Phospholipase D (PLD1 and PLD2) activities are stimulated in viral infection. In vitro studies indicate that chemical inhibition of PLD1 delays viral entry and reduction of viral loads. The current study reports a three-dimensional pharmacophore model based on 35 known PLD1 inhibitors. A sub-set of 25 compounds was selected as the training set and the remaining 10 compounds were kept in the test set. One hundred and twelve pharmacophore models were generated; a six-featured pharmacophore model (AADDHR.57) with survival score (2.69) produced a statistically significant three-dimensional quantitative structure–activity relationship model with r² = 0.97 (internal training set), r² = 0.71 (internal test set) and Q² = 0.64. The predictive power of the pharmacophore model was validated with an external test set (r² = 0.73) and a systematic virtual screening work-flow was employed showing an enrichment factor of 23.68 at the top 2% of the dataset (active and decoys). Finally, the model was used for screening of the filtered PubChem database to fetch molecules which can be proposed as potential PLD1 inhibitors for blocking influenza infection.     

离子凝聚法制备负载流感疫苗的壳聚糖微球

采用三聚磷酸钠(TPP)作为离子交联剂, 应用离子凝聚法制备负载流感疫苗的壳聚糖微球. 筛选出壳聚糖起始质量分数为1%. TPP的浓度对壳聚糖微球的制备影响较大, 采用低浓度的TPP(200 μg/mL)制备的微球放置过夜均出现沉淀现象, 高浓度的TPP(800 μg/mL)在制备过程中出现絮状沉淀. 固化比影响微球的释放行为, 固化比为1∶1的微球爆炸式释放率达到90％, 固化比为1∶3的微球6 h后逐步释放, 12 h后释放率达到95％. 固化比为1∶5的微球6 h后没有明显的释放行为. 壳聚糖溶液的pH对微球的制备和释放没有显著的影响. 通过对负载流感疫苗的壳聚糖微球的制备条件和释放行为的研究结果表明, pH=5.6的壳聚糖溶液, 固化比为1∶3, TPP的质量浓度为400 μg/mL是较理想的流感疫苗壳聚糖微球的制备条件.     

Electrochemical Detection of Avian Influenza Virus Genotype Using Amino‐ssDNA Probe Modified Gold Electrodes

A DNA biosensor for the detection of specific oligonucleotide sequences of Avian Influenza Virus type H5N1 has been proposed. The NH₂‐ssDNA probe was deposited onto a gold electrode surface to form an amide bond between the carboxyl group of thioacid and the amino group from ssDNA probe. The signals generated as a result of hybridization were registered in square wave voltammetry and electrochemical impedance spectroscopy in the presence of [Fe(CN)₆]^3?/4? as a redox marker. The genosensor is capable to determine 20‐mer and 180‐bp (PCR products) oligonucleotides complementary sequences with detection limit in the fM range. The genosensor displays good selectivity and sensitivity. The 20‐mer as well as 180‐bp oligonucleotides without a complementary sequence generate very low signal.